Master iron regulatory hormone produced by Liver hepatocytes in response to inflammatory signals and iron status. Controls systemic iron Homeostasis by binding and degrading ferroportin, the sole cellular iron exporter, thereby blocking iron absorption in the gut and sequestering iron in macrophages and hepatocytes. This creates hypoferremia (low serum iron) during inflammation and infectious disease as part of nutritional immunity.
Think of hepcidin as the central bank governor who controls how much currency (iron) flows through the economy. When the bank (hepatocytes) detects economic instability (inflammation), it immediately issues new regulations (hepcidin molecules) that lock all the vault doors (ferroportin channels). The grocery store (enterocytes) can no longer release newly purchased currency into circulation, and the recycling centers (macrophages breaking down old red blood cells) must hold onto their recovered currency instead of returning it to circulation. The result? The circulating money supply (serum iron) drops dramatically, even though the vaults are full (Ferritin stores are high). This isn't a malfunction β it's deliberate policy. By starving the economy of circulating currency, the bank prevents thieves (pathogens) from accessing the resources they need to thrive. The IL-6 alarm signal from immune cells is like an emergency hotline directly to the bank governor's office, triggering immediate lockdown within hours. The problem arises when the "emergency" becomes chronic β the vaults stay locked indefinitely (anemia of chronic disease), and legitimate businesses (your cells needing iron for Hemoglobin, enzymes, energy production) can't access the currency they need to function.
Hepcidin (encoded by HAMP gene, 25-amino acid peptide) synthesis and action pathway:
Synthesis Induction:
- Inflammatory pathway: Interleukin-6 β binds IL-6 receptor β activates JAK-STAT3 signaling β STAT3 phosphorylation β STAT3 dimerization and nuclear translocation β binds HAMP gene promoter β transcription of hepcidin mRNA β translation to hepcidin peptide
- Iron overload pathway: High iron β increased diferric transferrin β binds transferrin receptor 1 (TfR1) β releases HFE protein β HFE binds TfR2 β stabilizes TfR2 β TfR2-HFE complex signals β upregulates BMP6 (bone morphogenetic protein 6) β BMP6 binds BMP receptors (ALK2/ALK3) on hepatocytes β activates SMAD1/5/8 β SMAD1/5/8 phosphorylation β complex with SMAD4 β nuclear translocation β binds BRE (BMP response element) on HAMP promoter β transcription
Hepcidin Action:
3. Hepcidin secreted into circulation β binds ferroportin (SLC40A1) on cell membrane of enterocytes, macrophages, hepatocytes β triggers conformational change β recruits Janus kinase 2 (JAK2) β JAK2 phosphorylates ferroportin β ubiquitination of ferroportin β internalization via CHC22 Clathrin-mediated endocytosis β lysosomal degradation of ferroportin β loss of iron export capacity β iron trapped intracellularly
Suppression Signals:
- EPO (erythropoietin) β signals erythroid iron demand β suppresses hepcidin via ERFE (erythroferrone) produced by erythroblasts β ERFE inhibits hepatic BMP6-SMAD signaling
- Hypoxia β HIF-2Ξ± activation β inhibits hepcidin transcription
- Iron deficiency β decreased diferric transferrin β reduced BMP6-SMAD signaling β decreased hepcidin
- Testosterone β suppresses hepcidin via unknown mechanism
graph TD
A[IL-6 from inflammation] --> B[JAK-STAT3 pathway]
B --> C[STAT3 binds HAMP promoter]
D[High iron/BMP6] --> E[SMAD1/5/8 pathway]
E --> C
C --> F[Hepcidin synthesis]
F --> G[Hepcidin secreted]
G --> H[Binds ferroportin]
H --> I[JAK2 activation]
I --> J[Ferroportin ubiquitination]
J --> K[Internalization & degradation]
K --> L[Iron export blocked]
L --> M[Hypoferremia]
N[EPO/ERFE signal] --> O[Suppress hepcidin]
P["Hypoxia/HIF-2Ξ±"] --> O
Q[Iron deficiency] --> O
Half-life & Kinetics:
- Circulating half-life: 1-3 hours
- Hepcidin induction by IL-6: detectable within 2-4 hours, peaks at 6-8 hours
- Ferroportin degradation: begins within 15-30 minutes of hepcidin binding, complete by 60 minutes
- Duration of effect: single hepcidin pulse blocks iron export for 24-48 hours (time required for new ferroportin synthesis)
Anemia of chronic disease (ACD/ACI) β The Hepcidin Paradox:
Hepcidin is the central mediator of the most common anemia worldwide outside of iron deficiency. In conditions with chronic inflammation (rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, obesity, cancer, COVID-19), persistent IL-6 elevation drives continuous hepcidin production. This creates the diagnostic paradox: low serum iron (<60 ΞΌg/dL) and low transferrin saturation (<20%), yet normal or elevated Ferritin (>100 ng/mL) because iron is sequestered in macrophages and hepatocytes but cannot be exported. The bone marrow is "starved" of iron despite adequate body stores.
Evolutionary Context β Nutritional immunity:
Hepcidin represents an evolutionarily ancient defense strategy: withhold iron from invading pathogens. Most bacteria require iron for essential enzymes (cytochromes, ribonucleotide reductase). By inducing hypoferremia within hours of infection, hepcidin creates a hostile environment for bacterial growth. This is why infectious disease typically causes rapid drops in serum iron β it's protective. The selfish immune system prioritizes pathogen clearance over oxygen-carrying capacity.
Clinical Thresholds & Diagnosis:
- Normal hepcidin: 29-254 ng/mL (wide range, assay-dependent)
- ACD pattern: hepcidin often >200 ng/mL with CRP >10 mg/L
- Diagnostic triad for ACD: Low serum iron, low transferrin saturation, high/normal Ferritin, elevated C-reactive protein
- Ferritin >100 ng/mL + CRP >5 mg/L suggests hepcidin-mediated sequestration
Intervention Implications:
- Treat the inflammation, not the iron: Iron supplementation in ACD often fails because hepcidin blocks absorption. Worse, excess iron supplementation can worsen Oxidative Stress (Fenton reaction: FeΒ²βΊ + HβOβ β FeΒ³βΊ + OHΒ· + OHβ»). Priority is reducing inflammatory drivers.
- Address root causes: Target gut dysbiosis, chronic stress, metabolic syndrome, infectious disease, or autoimmune triggers driving IL-6 elevation
- Timing matters: If iron supplementation is necessary (concurrent true deficiency), consider anti-inflammatory interventions first to suppress hepcidin, or use parenteral iron to bypass gut regulation (though this doesn't solve ferroportin blockade)
- Monitor inflammation markers: Track CRP, IL-6, hepcidin alongside Ferritin and serum iron to distinguish ACD from iron deficiency anemia
Special Populations:
- Pregnancy: Hepcidin naturally suppressed (placental lactogen effect) to increase iron availability for fetus β but inflammatory complications can override this
- Chronic kidney disease: Hepcidin clearance reduced (normally filtered by kidneys) + inflammatory milieu = severe ACD, requiring erythropoiesis-stimulating agents
- Obesity: Adipose inflammation β chronic IL-6 elevation β hepcidin excess β contributes to metabolic dysfunction
Connection to Metamodels:
- Metamodel 1 (Selfish Systems): Immune system's hepcidin-mediated iron sequestration prioritizes infection defense over oxygen delivery
- Metamodel 2 (Evolutionary Mismatch): Chronic inflammation from modern lifestyle (processed food, sedentary behavior, chronic stress) triggers an acute defense mechanism (hepcidin) indefinitely β mismatch between acute adaptation and chronic trigger
- Metamodel 5 (Intervention): Multi-system approach required β cannot treat hepcidin-mediated anemia with single-system iron supplementation
- Encoded by HAMP gene on chromosome 19; synthesized as 84-amino acid preprohormone, cleaved to active 25-amino acid peptide
- Half-life 1-3 hours; requires continuous synthesis to maintain effect
- Induced within 2-4 hours by IL-6 via JAK-STAT3; peaks at 6-8 hours post-inflammatory stimulus
- Ferroportin degradation begins within 15-30 minutes of hepcidin binding; complete by 60 minutes
- Single hepcidin pulse blocks iron export for 24-48 hours (ferroportin resynthesis time)
- Normal range: 29-254 ng/mL (highly assay-dependent; not routinely measured clinically)
- Elevated in: inflammation, infectious disease, obesity, chronic kidney disease, cancer, iron overload, Pregnancy complications with inflammation
- Suppressed in: iron deficiency anemia, hypoxia, high EPO states (anemia, high altitude), hemochromatosis mutations (HFE, TfR2), Pregnancy (normal), testosterone therapy
- Mediates >80% of anemia of chronic disease cases worldwide
- Ferroportin is sole mammalian cellular iron exporter β no backup pathway exists; hepcidin block is absolute
- Ferroportin β hepcidin's sole molecular target; binding triggers JAK2-mediated ubiquitination and lysosomal degradation within 60 minutes
- Interleukin-6 β primary inflammatory inducer of hepcidin via JAK-STAT3 pathway; detectable hepcidin rise within 2-4 hours of IL-6 spike
- Iron β hepcidin is master regulator of systemic iron homeostasis; suppressed by deficiency, induced by overload via BMP6-SMAD pathway
- Anemia of chronic disease β hepcidin elevation is the central pathophysiological mechanism causing hypoferremia despite adequate iron stores
- Ferritin β elevated in ACD because hepcidin traps iron in ferritin-storing cells (macrophages, hepatocytes) while serum iron drops
- Nutritional immunity β hepcidin-induced hypoferremia withholds iron from bacterial pathogens as evolutionarily conserved defense strategy
- Hypoferremia β low serum iron is direct result of hepcidin blocking ferroportin-mediated iron export from enterocytes and macrophages
- Inflammation β chronic inflammatory states (rheumatoid arthritis, inflammatory bowel disease, obesity) drive persistent hepcidin elevation via IL-6
- C-reactive protein β clinical marker of inflammation; CRP >5 mg/L suggests hepcidin-mediated iron sequestration if accompanied by low serum iron
- EPO β erythropoietin signals iron demand and suppresses hepcidin via ERFE (erythroferrone) to mobilize iron for erythropoiesis
- Liver β hepatocytes are sole significant source of circulating hepcidin; hepatic inflammation or dysfunction alters hepcidin regulation
- infectious disease β bacterial and viral infections trigger rapid hepcidin induction via IL-6 to create hostile low-iron environment for pathogens
- Oxidative Stress β inappropriate iron supplementation in high-hepcidin states worsens oxidative damage via Fenton chemistry without correcting anemia
- obesity β adipose tissue inflammation and IL-6 secretion from adipocytes drives hepcidin elevation and contributes to obesity-associated anemia
- Chronic kidney disease β reduced hepcidin clearance plus inflammatory milieu creates severe ACD; hepcidin can exceed 500 ng/mL
- Pregnancy β hepcidin normally suppressed by placental hormones to increase iron transfer to fetus; inflammatory complications can override suppression
- Hemoglobin β ultimate target of hepcidin dysregulation; ACD reduces Hemoglobin synthesis despite adequate iron stores due to sequestration
- gut dysbiosis β intestinal inflammation from dysbiosis elevates IL-6 and hepcidin, reducing dietary iron absorption via enterocyte ferroportin degradation
- chronic stress β HPA-axis dysregulation and inflammation can drive hepcidin elevation as part of chronic inflammatory phenotype
- rheumatoid arthritis β classic ACD condition; synovial IL-6 drives systemic hepcidin, creating anemia despite normal/high Ferritin